COM:VERATX
Vera Therapeutics, Inc.
- Stock
Last Close
45.75
21/11 21:00
Market Cap
2.00B
Beta: -
Volume Today
401.03K
Avg: -
Preview
Full access to financials is available to subscribers only. Please support our work and get full access to all features. You can cancel anytime. If you'd like a demo, free trial or have any questions, please checkout the help page
Dec '19 | Dec '20 | Dec '21 | Dec '22 | Dec '23 | ||
|---|---|---|---|---|---|---|
average inventory | 236K - | 236K 0% | ||||
average payables | 625.50K - | 1.15M 83.37% | 6.69M 483.09% | 11.55M 72.76% | ||
average receivables | 26K - | 26K 0% | ||||
book value per share | -8.97 - | -21.92 144.47% | 5.18 123.63% | 2.89 44.12% | 2.38 17.74% | |
capex per share | -0.03 - | -0.02 20.80% | -0.00 - | -0.00 36.78% | ||
capex to depreciation | -0.25 - | -0.39 60.61% | 0.07 - | 0.02 78.96% | ||
capex to operating cash flow | 0.01 - | 0.00 76.59% | 0.00 - | 0.00 25.49% | ||
capex to revenue | ||||||
cash per share | 0.78 - | 13.16 1,579.31% | 5.93 54.95% | 6.99 17.95% | 6.46 7.69% | |
days of inventory on hand | ||||||
days payables outstanding | ||||||
days sales outstanding | ||||||
debt to assets | 0.02 - | 0.00 99.85% | 0.06 160,243.73% | 0.24 304.93% | 0.30 25.19% | |
debt to equity | -0.00 - | -0.00 99.38% | 0.07 316,127.85% | 0.41 475.05% | 0.51 26.47% | |
dividend yield | ||||||
earnings yield | -0.25 - | -1.14 350.59% | -0.09 92.03% | -0.17 90.69% | -0.15 15.63% | |
enterprise value | 43.81M - | -6.77M 115.46% | 284.25M 4,296.19% | 430.78M 51.55% | 549.83M 27.64% | |
enterprise value over ebitda | -3.97 - | 0.14 103.41% | -8.26 6,198.63% | -4.74 42.65% | -5.39 13.73% | |
ev to operating cash flow | -4.26 - | 0.19 104.57% | -11.99 6,261.00% | -6.37 46.85% | -5.96 6.40% | |
ev to sales | ||||||
free cash flow per share | -2.55 - | -8.56 235.20% | -1.76 79.39% | -2.55 44.31% | -2.16 15.18% | |
free cash flow yield | -0.22 - | -0.74 235.20% | -0.07 91.13% | -0.13 99.27% | -0.14 6.72% | |
graham net net | -9.50 - | -22.07 132.28% | 4.88 122.09% | 4.94 1.35% | 4.73 4.35% | |
graham number | 24.22 - | 80.39 231.90% | 16.82 79.08% | 14.77 12.15% | 10.97 25.73% | |
income quality | 0.87 - | 0.65 24.92% | 0.73 11.56% | 0.76 4.40% | 0.96 26.52% | |
intangibles to total assets | 0 - | 0 | 0 | 0 | 0 | |
interest coverage | -234.53 - | -314.70 34.19% | -1.72K 446.58% | -91.64 94.67% | 26.94 129.40% | |
interest debt per share | 0.04 - | 0.04 8.20% | 0.37 792.67% | 1.21 230.20% | 1.14 6.46% | |
inventory turnover | ||||||
invested capital | -0.00 - | -0.00 99.38% | 0.07 316,127.85% | 0.41 475.05% | 0.51 26.47% | |
market cap | 46.88M - | 46.88M 0% | 359.00M 665.82% | 514.14M 43.21% | 656.83M 27.75% | |
net current asset value | -38.36M - | -89.64M 133.66% | 68.38M 176.28% | 71.17M 4.08% | 98.16M 37.92% | |
net debt to ebitda | 0.28 - | 1.07 286.48% | 2.17 102.49% | 0.92 57.79% | 1.05 14.38% | |
net income per share | -2.91 - | -13.10 350.59% | -2.43 81.48% | -3.35 38.10% | -2.25 32.94% | |
operating cash flow per share | -2.52 - | -8.54 238.31% | -1.76 79.34% | -2.54 44.17% | -2.16 15.16% | |
payables turnover | ||||||
receivables turnover | ||||||
research and ddevelopement to revenue | ||||||
return on tangible assets | -2.20 - | -0.98 55.56% | -0.39 60.23% | -0.68 74.02% | -0.55 19.30% | |
revenue per share | ||||||
roe | 0.32 - | 0.60 84.32% | -0.47 178.38% | -1.16 147.12% | -0.94 18.48% | |
roic | 0.33 - | 0.58 77.36% | -0.46 178.96% | -0.79 71.70% | -0.66 17.19% | |
sales general and administrative to revenue | ||||||
shareholders equity per share | -8.97 - | -21.92 144.47% | 5.18 123.63% | 2.89 44.12% | 2.38 17.74% | |
stock based compensation to revenue | ||||||
tangible asset value | -36.55M - | -89.35M 144.47% | 69.59M 177.89% | 76.91M 10.51% | 101.69M 32.22% | |
tangible book value per share | -8.97 - | -21.92 144.47% | 5.18 123.63% | 2.89 44.12% | 2.38 17.74% | |
working capital | 2.50M - | 51.85M 1,970.06% | 74.85M 44.34% | 100.10M 33.74% | 149.72M 49.57% |
All numbers in (except ratios and percentages)